Rosiglitazone-induced myocardial protection against ischaemia-reperfusion injury is mediated via a phosphatidylinositol 3-kinase/Akt-dependent pathway.

@article{Zhang2010RosiglitazoneinducedMP,
  title={Rosiglitazone-induced myocardial protection against ischaemia-reperfusion injury is mediated via a phosphatidylinositol 3-kinase/Akt-dependent pathway.},
  author={X Q Zhang and Zi-Bo Xiong and An-li Tang and Hong Ma and Yue-dong Ma and Jing-Guo Wu and Yu-gang Dong},
  journal={Clinical and experimental pharmacology & physiology},
  year={2010},
  volume={37 2},
  pages={156-61}
}
1. Rosiglitazone is widely used in the treatment of Type 2 diabetes. However, in recent years it has become evident that the therapeutic effects of peroxisome proliferator-activated receptor gamma ligands reach far beyond their use as insulin sensitizers. Recently, the ability of rosiglitazone pretreatment to induce cardioprotection following ischaemia-reperfusion (I/R) has been well documented; however, the protective mechanisms have not been elucidated. In the present study, examined the role… CONTINUE READING